Oramed Pharmaceuticals Parties Intend For JV To Initiate Phase 3 Oral Insulin Trial In The U.S.; Oramed Will Be Entitled To Receive A 3% Royalty On Gross Revenues Of JV Generated From Oramed Related Assets
Oramed Pharmaceuticals Parties Intend For JV To Initiate Phase 3 Oral Insulin Trial In The U.S.; Oramed Will Be Entitled To Receive A 3% Royalty On Gross Revenues Of JV Generated From Oramed Related Assets
Oramed製藥雙方打算讓合資企業在美國啓動3期口服胰島素試驗；Oramed將有權從Oramed相關資產產生的合資企業總收入中獲得3％的特許權使用費
Oramed Pharmaceuticals Parties Intend For JV To Initiate Phase 3 Oral Insulin Trial In The U.S.; Oramed Will Be Entitled To Receive A 3% Royalty On Gross Revenues Of JV Generated From Oramed Related Assets
Oramed製藥雙方打算讓合資企業在美國啓動3期口服胰島素試驗；Oramed將有權從Oramed相關資產產生的合資企業總收入中獲得3％的特許權使用費
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。